19 results about "Refractory Disease" patented technology

The invention provides an antibody drug conjugate containing a functional small molecule side chain. The antibody drug conjugate is used for enhancing the targeted therapeutic effect of cancers and refractory diseases. The invention also relates to a preparation method of the conjugate, a pharmaceutical composition and a method for treating refractory diseases.

The present invention relates to an antibody-drug conjugate containing two or more functional small molecules for enhancement of targeted treatment of cancers and refractory diseases. The invention also relates to preparation of such conjugate, pharmaceutical compositions, and methods in treatment of cancers and refractory diseases.

Provided herein is a preparation of a stable drug conjugate containing one or two opened ring structures of thiosuccinimides linked to an antibody or an antibody-like protein for enhancement of targeted treatment of cancers and refractory diseases. In particular, provided herein are preparation of such conjugate homogenously, and its pharmaceutical compositions, as well methods in treatment of refractory diseases.

The present invention relates to a composition for preventing or treating bladder diseases, a composition for preventing or treating neuropathic pain, neuroinflammation or inflammatory skin diseases, or the therapeutic use of a novel compound YJ102, the compound YJ102 of the present invention inhibits neuropathic pain due to various reasons, ameliorates urination disorders due to spinal cord injury, restores bladder hypertrophy and bladder function, inhibits erythema and keratinogenesis, which are main symptoms of psoriasis, in a psoriasis animal model, and has a superior effect than conventional drugs. The composition can inhibit increase of the thickness of the epidermal layer and spleen hypertrophy caused by psoriasis, and can be used for treating various difficult nervous system diseases or bladder diseases.

The humanized monoclonal antibodies and the antibody drug conjugates targeting CD276 (B7-H3), derived from the murine monoclonal antibody clone 8H9. These antibodies and the antibody drug conjugates exhibit high affinity and specificity for human CD276, a member of the B7 family of immune regulatory proteins, which is overexpressed in various tumors and involved in immune checkpoint modulation. The humanized antibodies and the antibody drug conjugates are applied for targeted treatment of cancers and refractory diseases.

The invention relates to the technical field of medicines, and particularly discloses application of ipropam in preparation of a medicine for treating immune thrombocytopenic purpura. Aiming at the clinical problem that the condition of a patient with refractory recurrent immune thrombotic thrombocytopenic purpura (iTTP) still progresses after the treatment of plasma exchange combined with hormone, repatumab and immune globulin is invalid, the complement abnormal activation marker of the patient is detected to be increased, which indicates that the complement bypass way participates in disease recurrence refractory; ipropam is combined with plasma exchange, hormone and rituximab for treatment. Results show that the hemoglobin and platelet count is significantly increased after treatment for 5 days, mental symptoms are improved in 9 days, creatinine returns to normal in 11 days, ADAMTS13 activity is less than 0.2 IU / dL in 14 days, an inhibitor turns negative, and ADAMTS13 activity, hemoglobin and platelet return to normal in the fifth week. According to the application, it is proved for the first time that ipropam can effectively reverse the pathological process of refractory iTTP by inhibiting complement bypass pathway activation, and a new treatment strategy is provided for the disease.

The application discloses a kind of PROTAC molecules with crizotinib as target head, preparation method and application, belong to the field of biological medicine;Preparation method includes: chloro carboxylic acid, thionyl chloride and anhydrous DMF are mixed, after heating reflux reaction, remove thionyl chloride, obtain acyl chloride;Pomalidomide, acyl chloride, organic solvent are mixed and reacted, then filtered to obtain intermediate M;Intermediate M, crizotinib, Na2CO3 are mixed and reacted, then filtered to obtain the PROTAC molecule with crizotinib as target head.The in vitro biological evaluation shows that the new PROTAC molecule can efficiently and selectively induce ubiquitination and degradation of target protein, and exhibits significant antiproliferative activity in drug-resistant tumor cell models and animal models;The application proves that the PROTAC molecule has great potential in overcoming drug resistance of traditional inhibitors, and provides a promising lead compound for developing new therapies for treating refractory diseases such as cancer.

The application relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating IgA nephropathy, which is prepared from the following raw medicinal materials in parts by weight: radix codonopsis 9-15 parts, radix astragali 9-15 parts, zingiberis rhizoma 6-9 parts, rhizoma pinelliae praeparatum 9-15 parts, radix scrophulariae 6-9 parts, rhizoma coptidis 3-6 parts, coix lacryma-jobi 15-45 parts, pyrrosia 9-15 parts, euonymus alatus 9-15 parts and licorice 3-9 parts. The application also includes the application of the traditional Chinese medicine composition in the preparation of medicines for treating IgA nephropathy. The application ingeniously applies the modern intractable disease to the formula, embodies the treatment principle of treating different diseases in the same way, the selected raw medicinal materials meet the compatibility principle of monarch, minister, assistant and messenger, have the effect of treating the principal and secondary symptoms at the same time, and the application effect is remarkable. The application provides a new treatment scheme for patients with IgA nephropathy, improves the survival rate of the patients, and has a good application prospect.

The invention relates to the field of medicine, in particular to a relation between ORMDL3 and HER2 positive diseases and application of an ORMDL3 degradation agent to the HER2 positive diseases, especially HER2 refractory diseases.

Methods for treatment of myeloproliferative neoplasms are provided, particularly in patients with poor bone marrow functioning, and difficult to treat human patients such as those with relapsed or refractory disease. The disclosed methods comprise administering Compound (1) having the following structure or a pharmaceutically acceptable salt thereof, and optionally a JAK kinase inhibitor and / or ACVR inhibitor, to a human subject in need thereof.

An antibody-drug conjugate comprising two or more functional small molecules for enhancing targeted treatment of cancers and refractory diseases, and methods for preparing such conjugates and pharmaceutical compositions thereof.

An antibody-drug conjugate containing a side chain of a functional small molecule for enhancement of targeted treatment of cancers and refractory diseases is provided. The preparation of such conjugate, pharmaceutical compositions, and methods in treatment of refractory diseases are also provided.

The invention belongs to the field of biological medicine and molecular biology, and particularly relates to novel orthogonal replication RNA (Ribonucleic Acid) as well as a preparation method and application thereof. The sequence of the orthogonally replicated RNA comprises: (a) a 5'untranslated region of the human norovirus; (b) an open reading frame 1 of human norovirus encoding a replicase; (c) an antisense coding sequence of the target gene; (d) replicating a termination signal and a 3'untranslated region; after the orthogonally replicated RNA is replicated in cells, sense mRNA which is covalently connected with Vpg protein at the 5'end and can translate the target gene can be generated. According to the application, the huNoV replicon is successfully engineered into a therapeutic OrepRNA platform for the first time, a brand new RNA drug carrier category is created, low immunogenicity and high fidelity can be realized, and the disease treatment bottleneck of cap-dependent translation limitation can be broken through. According to the platform, various diseases with different pathological mechanisms can be solved by matching different treatment genes, the ductility is high, and a breakthrough treatment scheme is provided for refractory diseases such as tumor cachexia and GVHD pulmonary fibrosis.

The present invention relates to a structure for surface-enhanced Raman scattering spectroscopy, a method for manufacturing the same, and a diagnostic method using the same. According to the structure for surface-enhanced Raman scattering spectroscopy, the method for manufacturing the same, and the diagnostic method using the same of the present invention, it is possible to provide a structure for surface-enhanced Raman scattering spectroscopy, which can be used as a surface-enhanced Raman scattering spectroscopy, even if there is no biomarker having excellent diagnostic performance in blood indexes. A structure for surface-enhanced Raman scattering spectroscopy, which can be used even for intractable cancers such as pancreatic cancer and intractable diseases, and a method for producing the same. Further, a diagnostic method and a diagnostic system using a surface-enhanced Raman scattering spectrum can be provided by the structure for the surface-enhanced Raman scattering spectrum.

The present disclosure provides methods of treating myeloproliferative tumors, particularly suitable for patients with bone marrow dysfunction and difficult to treat, such as human patients with recurrent or refractory diseases. The disclosed methods comprise administering to a human subject in need thereof a compound having the following structure (1): # imgabs0 # or a pharmaceutically acceptable salt thereof, and optionally a JAK kinase inhibitor and / or an ACVR inhibitor.

The present disclosure relates to a structure for surface-enhanced Raman scattering spectroscopy, a method of preparing the same, and a diagnostic method using the same. According to the structure for surface-enhanced Raman scattering spectroscopy, the method of preparing the same, and the diagnostic method using the same, of the present disclosure, a structure for surface-enhanced Raman scattering spectroscopy and a method of preparing the same may be provided, which can be used even when biomarkers with excellent diagnostic performance among blood indicators do not exist, as in the case of intractable cancer, such as pancreatic cancer, and intractable diseases. Also, a diagnostic method and diagnostic system using surface-enhanced Raman scattering spectroscopy may be provided by using the structure for surface-enhanced Raman scattering spectroscopy.

To establish close cooperation between a doctor, a pharmacist, and a patient to improve the quality of medical treatment of the patient.SOLUTION: A cooperation system 10 includes: a terminal for a patient 20 that is used by a patient U; a terminal for a doctor in charge 30 that is used by a doctor in charge D; a terminal for a pharmacist 40 that is used by a pharmacist P; and a control unit 50 that establishes a data communication environment between the terminal for a patient 20 and the terminal for a pharmacist 40 and between the terminal for a doctor in charge 30 and the terminal for a pharmacist 40, and controls the entire system 10, and the control unit 50 provides a learning tool for learning about the disease of the patient U to the terminal for a pharmacist 40. This enables the pharmacist P to perform operations to support the patient U with deep knowledge about the disease of the patient even if the patient U has an incurable disease, which allows the pharmacist P to establish close cooperation among the three and allows the improvement in the quality of the medical treatment of the patient U.SELECTED DRAWING: Figure 1

A method for treating myeloproliferative neoplasms is provided, particularly for treating human patients with poor bone marrow function and relapsed or refractory diseases that are difficult to treat. The disclosed method has the following structure: [Case 1] The method comprises administering a compound (1) having JPEG2026509318000030.jpg3762 or a pharmaceutically acceptable salt thereof, and optionally a JAK kinase inhibitor and / or an ACVR inhibitor, to a human subject in need.

The invention provides application of hematopoietic stem progenitor cells in treatment of keloid. The umbilical cord blood-derived hematopoietic stem cells have an obvious inhibition effect on growth of keloid. Specifically, a PDX (Patient-Derived Xenogram) Balb / c-nu immunodeficient mouse model is adopted to research the treatment effect of human hematopoietic stem cells on keloid, and the result shows that the size and the weight of a graft are effectively reduced through HSCs treatment. In conclusion, the growth of the keloid can be obviously inhibited by the umbilical cord blood-derived hematopoietic stem cells, theoretical support can be provided for clinical application of an umbilical cord blood bank in inflammation-related fibrosis diseases (lung injury, spinal cord injury, myocardial infarction, corneal injury, renal fibrosis, cirrhosis and the like), and the application value is expanded; meanwhile, a new thought and a new prospect can be provided for clinical treatment of the intractable disease, namely keloid in the future.